Replies to post #37981 on OncoSec Medical Inc (ONCSQ)

[Titan V]

My notes from the webcast:
- PD said they plan to monetize TRACE technology this year
- PD said they will be announcing collaborations for TRACE via the TAP shortly
- On track to commence patient enrollment for registration trial in Q2 2017
- Plan is to move ahead with the registration trial with a multinational
- Exit opportunity may present itself within the next 18 months for lead program (EP IL-12 + anti-PD1)
- I understood the above statement as they will retain TRACE tech, and opportunities to partner it out beyond anti-PD1 candidates in the event of a sale of the lead candidate; PD talks about keeping a piece of the pie

Audio from the webcast to verify the above (30 mins):
https://event.webcasts.com/viewer/event.jsp?ei=1130360